These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33817409)

  • 21. Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab.
    Ho TC; Maamari RN; Kossler AL; Sears CM; Freitag SK; Reshef ER; Shinder R; Rootman DB; Diniz SB; Kahana A; Schlachter D; Do TH; Kally P; Turner S; Mokhtarzadeh A; Harrison AR; Hwang CJ; Kim HJ; Avila SA; Thomas DA; Magazin M; Wester ST; Lee WW; Clauss KD; Holds JB; Sniegowski M; Compton CJ; Briggs C; Malik AI; Lucarelli MJ; Burkat CN; Patel LG; Couch SM
    Ophthalmic Plast Reconstr Surg; 2023 Mar-Apr 01; 39(2):150-155. PubMed ID: 36095848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
    Kossler AL; Douglas R; Dosiou C
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series.
    Chu M; Sung J; Song M; Song A; Song J
    J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.
    Douglas RS
    Eye (Lond); 2019 Feb; 33(2):183-190. PubMed ID: 30575804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report.
    Lu TJ; Amarikwa L; Winn BJ; Inserra M; Dosiou C; Kossler AL
    Case Rep Ophthalmol; 2023; 14(1):134-139. PubMed ID: 37034380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Adverse Effects Profile of Teprotumumab.
    Stan MN; Krieger CC
    J Clin Endocrinol Metab; 2023 Aug; 108(9):e654-e662. PubMed ID: 37071658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Teprotumumab for Thyroid-Associated Ophthalmopathy.
    Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
    N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Teprotumumab-Related Hyperglycemia.
    Amarikwa L; Mohamed A; Kim SH; Kossler AL; Dosiou C
    J Clin Endocrinol Metab; 2023 Mar; 108(4):858-864. PubMed ID: 36300333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teprotumumab for chronic thyroid eye disease.
    Ozzello DJ; Dallalzadeh LO; Liu CY
    Orbit; 2022 Oct; 41(5):539-546. PubMed ID: 34060414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Interesting Case of Euthyroid Graves' Ophthalmopathy, With Negative Thyroid-Stimulating Hormone Receptor Antibodies.
    Moeen Z; Aliuddin AM; Gray Wlazlo T; Majid H; Kolli S
    Cureus; 2021 Oct; 13(10):e19015. PubMed ID: 34853745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of teprotumumab on patients with long-standing, active thyroid eye disease.
    Vinson KB; Kirzhner M
    Am J Ophthalmol Case Rep; 2022 Jun; 26():101348. PubMed ID: 35402750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report.
    Ding AS; Mahoney NR; Campbell AA; Creighton FX
    Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.
    Douglas RS; Dailey R; Subramanian PS; Barbesino G; Ugradar S; Batten R; Qadeer RA; Cameron C
    JAMA Ophthalmol; 2022 Apr; 140(4):328-335. PubMed ID: 35175308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
    Sears CM; Azad AD; Amarikwa L; Pham BH; Men CJ; Kaplan DN; Liu J; Hoffman AR; Swanson A; Alyono J; Lee JY; Dosiou C; Kossler AL
    Am J Ophthalmol; 2022 Aug; 240():1-13. PubMed ID: 35227694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease.
    Teo HM; Smith TJ; Joseph SS
    Ther Clin Risk Manag; 2021; 17():1219-1230. PubMed ID: 34858025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Teprotumumab-Induced Encephalopathy: A Rare Side Effect of a Novel Therapeutic.
    Yee MD; McCarthy J; Quinn B; Surani A
    WMJ; 2023 May; 122(2):134-137. PubMed ID: 37141481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement of asymmetric thyroid eye disease with teprotumumab.
    Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R
    Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach.
    Douglas RS; Kossler AL; Abrams J; Briceño CA; Gay D; Harrison A; Lee M; Nguyen J; Joseph SS; Schlachter D; Tan J; Lynch J; Oliver L; Perry R; Ugradar S
    J Neuroophthalmol; 2022 Sep; 42(3):334-339. PubMed ID: 35421877
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.